论文部分内容阅读
采用RT-PCR法、化学比色法对60例经纤维支气管镜活检的肺癌组织及20例非癌组织进行酸性各胱甘肽S-转移酶(GST-π)检测,并动态检测肺癌患者化疗前后血浆GST-π活力。结果显示GST-π在肺癌组织中的表达阳性率45％(27/60)明显高于非癌组织的表达阳性率13.3％(3/20),腺癌阳性率最高64.7％(11/17),鳞状细胞癌次之45.5％(15/33)、小细胞未分化癌无阳性表达。肺癌组织中GST-π的表达与血浆GST-π活力呈正相关(P<0.05)。肺癌患者血浆GST-π水平明显高于对照组,与疗效呈正相关(P<0.05)。肺癌GST-π基因表达及化疗前后血浆GST-π活力变化对肺癌化疗方案的选择及疗效判断均有一定指导意义。
Sixty patients with bronchofibroma biopsy and 20 patients with non-cancerous tissue were tested for the activity of GST-π by RT-PCR and chemiluminescence method, and the chemosensitivity of lung cancer patients Plasma GST-π activity before and after. The positive rate of GST-π expression in lung cancer was 45% (27/60), significantly higher than that in non-cancerous tissues (13.3%, 3/20) and the highest positive rate was 64.7% (11/17) , Squamous cell carcinoma 45.5% (15/33), small cell undifferentiated carcinoma without positive expression. The expression of GST-π in lung cancer tissues was positively correlated with plasma GST-π activity (P <0.05). Plasma GST-π level in patients with lung cancer was significantly higher than that in the control group, with a positive correlation (P <0.05). The expression of GST-π gene in lung cancer and the change of plasma GST-π activity before and after chemotherapy have certain guiding significance for the choice of chemotherapy regimen and curative effect of lung cancer.